Azimilide for atrial fibrillation: Clinical trial results and implications

Cardiac Electrophysiology Review

Volumn 7, Issue 3, 2003, Pages 215-219

  Pritchett, Edward L C ^a,b,c   Marcello, Stephen R ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^c NONE   (United States)

Author keywords

Antiarrhythmic drug therapy; Atrial fibrillation; Azimilide

Indexed keywords

ANTIARRHYTHMIC AGENT; AZIMILIDE; PLACEBO;

ANAMNESIS; ANTIARRHYTHMIC ACTIVITY; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; HEADACHE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART SUPRAVENTRICULAR ARRHYTHMIA; HUMAN; INFECTION; MORTALITY; NEUTROPENIA; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SYMPTOMATOLOGY; TORSADE DES POINTES;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ATRIAL FLUTTER; ELECTROCARDIOGRAPHY; HUMANS; IMIDAZOLES; IMIDAZOLIDINES; MYOCARDIAL INFARCTION; PIPERAZINES; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 1342265974     PISSN: 13852264     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:CEPR.0000012385.15778.d2     Document Type: Article

References (10)

1. Pritchett ELC. Azimilide: A review of clinical studies. In: Tse H-F, Lee KLF, Lau C-P, eds. Bologna, Italy: Monduzzi Editore, 2003:945-952.
2. Salata JJ, Brooks RR. Pharmacology of Azimilide Dihydrochloride (NE-10064), a class III antiarrhythmic agent. Cardiovascular Drug Reviews 1997;15:137-156.
3. Connolly SJ, Schnell DJ, Page RL, Wilkinson WE, Marcello S, Pritchett ELC. Dose-response relationships of azimilide in the management of symptomatic, recurrent atrial fibrillation. Am J Cardiol 2001;88(9):974-979.
4. Page RL, Connolly SJ, Wilkinson WE, Marcello SR, Schnell D, Pritchett ELC, Azimilide Supraventricular Arrhythmia Program Investigators. Antiarrhythmic effects of azimilide in paroxysmal supraventricular tachycardia: Efficacy and dose-response. Am Heart J 2002;143:643-649.
5. Pritchett ELC, Page RL, Connolly SJ, Marcello SR, Schnell DJ, Wilkinson WE, Azimilide Supraventricular Arrhythmia Program 3 (SVA-3) Investigators. Antiarrhythmic effects of azimilide in atrial fibrillation. Efficacy and doseresponse. J Am Coll Cardiol 2000;36:794-802.
6. Anderson JL, Gilbert EM, Alpert BL, Henthorn RW, Waldo AL, Bhandari AK, Hawkinson RW, Pritchett ELC, and the Flecainide Supraventricular Tachycardia Study Group. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Circulation 1989;80:1557-1570.
7. Camm AJ, Pratt CM, Schwartz PJ, Al-Khalidi H, Spyt M, Holroyde MJ, Karam R, Sonnenblick EH, Brum JM. Azimilide Post Infarct Survival Evaluation (ALIVE): Azimilide does not affect mortality in post-myocardial infarction patients. Circulation 2001;104(25):104.
8. Pratt CM, Singh BN, Al-Khalidi H, Brum JM, Holroyde MJ, De Ferrari GM, Schwartz PJ, Matteo PS, Camm AJ. Efficacy of azimilide in treatment of atrial fibrillation in a high-risk post-myocardial infarction population. Circulation 2002;106-II(19):634.
9. Torp-Pederson C, Moller M, Bloch-Thomsen PE, Kober L, Sandoe E, Egstrup K, Agner E, Carlsen J, Vidabaek J, Marchant B, Camm AJ. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med 1999;341(12):857-865.
10. Pritchett ELC, Schulte MC, Schnell D, Marcello SR, Wilkinson WE, Page RL, Azimilide Supraventricular Arrhythmia Program 3 (SVA-3) Investigators. Effects of azimilide on heart rate and ECG conduction intervals during sinus rhythm in patients with a history of atrial fibrillation. J Clin Pharm 2002;42(4):388-394.